CBT + Trazodone for Insomnia
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how two common treatments for insomnia work for people with different sleep patterns. Participants with chronic insomnia will first try Cognitive Behavioral Therapy for Insomnia (CBT-I), a type of talk therapy. If CBT-I proves ineffective, they will receive either trazodone, a non-addictive sleep medication, or a placebo. The trial aims to determine if individuals with short or normal sleep durations respond differently to these treatments. Those with chronic insomnia and a BMI of 18.5 or higher might be suitable candidates. As an Early Phase 1 trial, this research focuses on understanding how these treatments work in people, offering participants a chance to contribute to foundational insomnia research.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop all current medications, but you cannot use medications for sleep more than twice a week, systemic corticosteroids, opiates, or any medications that don't mix well with trazodone. You must also continue your anti-hypertensive medication if you're on it.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that both treatments in this study are safe. Cognitive Behavioral Therapy for Insomnia (CBT-I) is a safe and effective method, with studies indicating long-lasting benefits and very few risks. Since it doesn't involve medication, there are no drug-related side effects.
Trazodone, used in a low dose for insomnia, is a commonly prescribed medication that is not addictive. Research has found that it can greatly improve sleep time without causing major side effects. However, like any medication, some people might experience mild side effects such as dizziness or a dry mouth.
Overall, both treatments are generally well-tolerated, with trazodone having a few possible mild side effects.12345Why are researchers excited about this trial's treatments?
Researchers are excited about combining Cognitive Behavioral Treatment for Insomnia (CBT-I) with trazodone because it offers a unique two-step approach to treating insomnia. While most treatments focus solely on either behavioral therapy or medication, this method starts with CBT-I, a well-established therapy that addresses the root causes of insomnia. If patients don't respond fully, trazodone, an antidepressant with sedative effects, is added to enhance sleep quality. This combination could offer a more comprehensive solution by tackling both psychological and physiological aspects of insomnia, potentially leading to better outcomes than current options like sleep medications or CBT-I alone.
What evidence suggests that this trial's treatments could be effective for insomnia?
Research shows that trazodone can help people with insomnia sleep longer, particularly those who typically sleep for a short duration. Trazodone also lowers blood pressure and reduces evening cortisol levels, a hormone related to stress. In this trial, some participants will receive Cognitive Behavioral Therapy for Insomnia (CBT-I) with trazodone. Conversely, CBT-I works well for individuals with insomnia who already sleep a normal amount, showing about a 30% higher success rate for this group. Other participants in this trial will receive CBT-I with a placebo. Both treatments effectively address long-term insomnia and have few side effects. These findings suggest that both trazodone and CBT-I can be helpful, but their success may depend on the type of insomnia present.13678
Who Is on the Research Team?
Alexandros Vgontzas, MD
Principal Investigator
Professor, Psychiatry
Are You a Good Fit for This Trial?
This trial is for adults with chronic insomnia, particularly those who sleep less than normal (ISS) or have a normal sleep duration (INS), and also have high blood pressure. Participants should not be currently using other treatments for insomnia.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Cognitive Behavioral Therapy for Insomnia (CBT-I) for 8 weeks. Non-remitting subjects then receive either trazodone or placebo for an additional 8 weeks.
Follow-up
Participants are monitored for remission of insomnia symptoms and other secondary outcomes such as cortisol levels and blood pressure.
What Are the Treatments Tested in This Trial?
Interventions
- Cognitive Behavioral Treatment for Insomnia (CBT-I)
- Placebo
- Trazodone
Find a Clinic Near You
Who Is Running the Clinical Trial?
Milton S. Hershey Medical Center
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator